Contineum Therapeutics Completes Enrollment in PIPE-307 VISTA Trial
Contineum Therapeutics, Inc. (NASDAQ: CTNM) has successfully completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial, aiming to innovate treatments for relapsing-remitting multiple sclerosis (RRMS). This groundbreaking biopharmaceutical company is known for its development of unique therapies addressing neuroscience, inflammation, and immunology.
Details of the PIPE-307 VISTA Trial
The Phase 2 trial is designed as a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study. It will evaluate both the safety and efficacy of the PIPE-307 treatment among RRMS patients. This trial is focused on measuring various clinical and imaging endpoints that are sensitive to remyelination changes.
Significance of the Phase 2 Trial
Completing patient enrollment ahead of schedule marks a significant milestone for the VISTA trial. Stephen Huhn, Chief Medical Officer at Contineum Therapeutics, expressed optimism about the trial, stating, "The trial is designed to show evidence of remyelination as a potentially first-in-class and differentiated therapy for RRMS patients. We believe that PIPE-307 could represent the next evolution in the treatment paradigm for RRMS." This enthusiasm underscores the potential impact of the research being undertaken.
Future Expectations for PIPE-307
As the trial moves forward, Contineum anticipates that the last patient will complete the study in the third quarter of 2025. Investigators, patients, and their families are all roles in this journey, with the company eager to share topline data as it becomes available.
Collaborative Efforts with Janssen Pharmaceuticals
PIPE-307’s development is conducted under a global license agreement with Janssen Pharmaceutica NV, a well-respected subsidiary of Johnson & Johnson. This partnership emphasizes a commitment to advancing innovative solutions for patients who face substantial health challenges, specifically those suffering from relapsing-remitting MS.
About Contineum Therapeutics
As a clinical-stage biopharmaceutical company, Contineum Therapeutics (NASDAQ: CTNM) specializes in developing novel oral small molecule therapies targeting NI&I indications with significant opportunities for improvement in patient health outcomes. The company is progressing a pipeline consisting of internally-developed drugs, with several candidates actively undergoing clinical trials.
Innovative Drug Candidates
Contineum is particularly excited about its pipeline. PIPE-791, an LPA1 receptor antagonist, aims to address idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain while PIPE-307 presents a selective approach for relapsing-remitting MS. This commitment to cutting-edge research demonstrates the company’s dedication to addressing critical medical needs.
Contact Information
To learn more about Contineum Therapeutics and ongoing projects, please visit their official website. The company is open to queries regarding its clinical advancements and partnership opportunities.
Frequently Asked Questions
What is the primary goal of the PIPE-307 VISTA trial?
The trial aims to assess the safety and efficacy of PIPE-307 in patients with relapsing-remitting multiple sclerosis.
How many patients were enrolled in the PIPE-307 trial?
The trial achieved enrollment of 168 patients, which is the targeted number for this study.
Who is the partnering company for CONTINUUM's PIPE-307?
Contineum is collaborating with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson, to develop PIPE-307.
When is the expected completion of the trial?
The last patient is anticipated to complete the study in the third quarter of 2025.
What innovative solutions does Contineum focus on?
Contineum Therapeutics focuses on developing novel, oral small molecule therapies for various neuroscience and immunology conditions.
